128 results about "Tissue protection" patented technology

An enhanced method and device are provided to treat atrial fibrillation or inhibit or reduce restenosis following angioplasty or stent placement. A balloon-tipped catheter is disposed in the area treated or opened through balloon angioplasty immediately following angioplasty. The balloon, which can have a dual balloon structure, may be delivered through a guiding catheter and over a guidewire already in place. A fluid such as a perfluorocarbon flows into the balloon to freeze the tissue adjacent the balloon, this cooling being associated with reduction of restenosis. A similar catheter may be used to reduce atrial fibrillation by inserting and inflating the balloon such that an exterior surface of the balloon contacts at least a partial circumference of the portion of the pulmonary vein adjacent the left atrium. In another embodiment, blood perfusion is performed simultaneously. In another embodiment, tissue contacted by the cryoablation catheter, undesired to be ablated, is protected against damage by a separate heating step.

A minimally invasive fixation system and method for providing access to a surgical site. The fixation system may include a holding assembly, the holding assembling preferably including a lateral implant holder which may be attached to a pedicle screw and a sleeve positioned in connection with the lateral implant holder to prevent the lateral implant holder from separating from the pedicle screw. The sleeve may further include a tissue protection portion to keep the tissue out of the surgical site. A holding sleeve may be operably connected to the holding assembly and pedicle screw and may be used to insert the pedicle screw into the body. Multiple constructs may be inserted into the body so that a portion of the holding assembly extends from the body and provides access to and visualization of the surgical site. A rod holder may also be used to insert a rod into the head of the screw. The rod may be held by the rod holder so that the rod may be angulated as the rod is inserted into the screw heads. Once the rod is positioned in the screw heads, locking caps and/or set screws may be positioned over the rod and engage the screw heads so that the position of the rod may be fixed with respect to the screws. In some embodiments, a movement mechanism may be used to move the screws relative to each other to compress and/or distract the vertebrae.

An enhanced method and device are provided to treat atrial fibrillation or inhibit or reduce restenosis following angioplasty or stent placement. A balloon-tipped catheter is disposed in the area treated or opened through balloon angioplasty immediately following angioplasty. The balloon, which can have a dual balloon structure, may be delivered through a guiding catheter and over a guidewire already in place. A fluid such as a perfluorocarbon flows into the balloon to freeze the tissue adjacent the balloon, this cooling being associated with reduction of restenosis. A similar catheter may be used to reduce atrial fibrillation by inserting and inflating the balloon such that an exterior surface of the balloon contacts at least a partial circumference of the portion of the pulmonary vein adjacent the left atrium. In another embodiment, blood perfusion is performed simultaneously. In another embodiment, tissue contacted by the cryoablation catheter, undesired to be ablated, is protected against damage by a separate heating step.

An ablation system is provided that includes an ablating device and a probe. The probe is configured to be positioned in close proximity to a region of non-targeted tissue proximate an ablation site of targeted tissue. The probe includes an elongate shaft having proximal and distal ends, with a handle disposed at the proximal end thereof and a tissue protecting apparatus disposed at the distal end thereof. The ablating device includes an elongate shaft having proximal and distal ends, with a handle mounted at the proximal end thereof and an ablation element mounted at the distal end thereof. The ablation element includes an ultrasound transducer and an inflatable balloon surrounding the ultrasound transducer. The balloon includes a layer of gel disposed on its outer surface.

A tissue protector is adapted to be positioned on the skin surrounding an incision. The tissue protector provides a load bearing surface for surgical tools and instruments to prevent blunt force and pressure trauma to the skin and soft tissues within the incision. In one embodiment, the tissue protector is a sheet of wear-resistant material having an opening corresponding to the incision and expandable as the incision is retracted. In another embodiment, a tissue protector device includes a continuous expandable arrangement of interconnected L-shaped links. In still another embodiment, a one-piece tissue protector includes a flexible panel supported on the skin and a flexible sleeve extending into the incision. Yet another embodiment of the invention resides in a track that is supported about the incision. An instrument support platform is slidably mounted to the track to support a surgical tool relative to the incision.

A device and method for cutting or ablating tissue in a human or veterinary patient includes an elongate probe having a distal end, a tissue cutting or ablating apparatus located adjacent within the distal end, and a tissue protector extending from the distal end. The protector generally has a first side and a second side and the tissue cutting or ablating apparatus is located adjacent to the first side thereof. The distal end is structured to be advanceable into tissue or otherwise placed and positioned within the patient's body such that tissue adjacent to the first side of the protector is cut away or ablated by the tissue cutting or ablation apparatus while tissue that is adjacent to the second side of the protector is not substantially damaged by the tissue cutting or ablating apparatus.

A tissue protective system and method having particular application in thermoablative surgical therapies where heat or cold is used to create a kill zone for treating cancer cells as well as malignant or benign tumors in a targeted internal tissue area (e.g., the prostate) of a patient while sparing an adjacent benign internal tissue area (e.g., a neurovascular bundle). One of a hollow sheath or a balloon that is carried by a balloon catheter is located within an access opening that is made by a needle trocar inserted between the targeted tissue area in need of treatment and the benign tissue area to be protected in order to hold the protected tissue area off the targeted tissue area and away from the lethal temperature of the kill zone. The balloon of the balloon catheter is inflated in the access opening via a balloon channel which runs longitudinally through the catheter. At least one temperature sensor is mounted on the balloon and responsive to the temperature near the benign tissue area to be protected. Heat or cold is provided to the balloon from a heating wire or a circulating fluid, depending upon the temperature that is sensed by the temperature sensor.

Methods and compositions are provided for protecting or enhancing a responsive cell, tissue, organ or body part function or viability in vivo, in situ or ex vivo in mammals, including human beings, by systemic or local administration of an erythropoietin receptor activity modulator, such as an recombinant tissue protective cytokine.

A surgical device and method for endoscopic surgical procedures capable of preventing injuries to internal organs during insertion. The surgical device can include one or more of the following: a multiple system of sharp blade edges or a single blade, a mechanical tissue protection device that includes a series of thin plastic guards sliding along the sides of the planar knives and having an angle between their edges smaller than that of the cutting knife edges, one or more fixed conical deflectors to expand the cut tissue passage leaving the guards to contact tissue contact only at their tips, an insufflation passage configured to transport fluid into the body cavity during penetration, a locking system for the guards that prevents accidental reuse of the cutting features, and/or an ergonomic design which facilitates handling.

A transvenous cardiac lead comprises a lead body having a distal end portion comprising a tip adapted to be placed in engagement with cardiac tissue. A protective device is carried by the distal end portion of the lead body in operative association with the tip, the protective device being deployable following placement of the tip to protect the cardiac tissue engaged by the tip. The deployable protective device may be expandable upon implantation to provide a larger surface area or footprint about the lead tip so as to retard or reduce the risk of penetration or perforation of the myocardium by the tip. The protective device may comprise a matrix expandable in response to contact with bodily fluids. Preferably, the expandable matrix comprises hydrogel. Alternatively, the protective device may comprise at least one electroactive polymer element electrically connected to a proximal end of the lead body.

A system for organizing, protecting, sterilizing, storing and delivery of surgical instruments, implants and related devices. Post and button fasteners are removably mounted to a tray and hold rigid and flexible bracketry for securing devices within the assembly. A flexible bar for holding items is mounted by a pair of rigid brackets in turn mounted either directly to the tray floor or to a base wall positioned atop the tray floor.

A method for fusing two adjacent stacked bones includes the following. First, inserting first and second pins into first and second locations of a first surface of one of the two adjacent stacked bones, respectively. Next, inserting a dilator over each of the first and second pins to dilate tissue around the first and second pins. Next, inserting a tissue protector over the dilator and removing the dilator. Next, inserting a cannulated drill through the tissue protector over each of the first and second pins and drilling first and second openings in the first and second locations, respectively, wherein the first and second opening extend through the two adjacent stacked bones. Next, tapping threads in the first opening and inserting a first bone fusing implant in the first opening, wherein the first bone fusing implant comprises threads configured to engage the threads of the first opening. Next, impacting a broach into the second opening to generate a pattern corresponding to a pattern of a second bone fusing implant and then inserting the second bone fusing implant in the second opening.

The present invention is directed to novel tissue protective peptides. The tissue protective peptides of the invention may bind to a tissue protective receptor complex. In particular, the present invention is drawn to tissue protective peptides derived from or sharing consensus sequences with portions of cytokine receptor ligands, including Erythropoietin (EPO), that are not involved in the binding of the ligand to the receptor complex, e.g., to the EPO receptor homodimer. Accordingly, the tissue protective peptides of the invention are derived from the amino acid sequences of regions of cytokine receptor ligands that are generally located on or within the region of the ligand protein that is opposite of the receptor complex, i.e., are generally derived from amino acid sequences of regions of the ligand protein that face away from the receptor complex while the ligand is bound to the receptor. The invention is further directed to the consensus sequences for use in engineering a synthetic tissue protective peptide. These tissue protective peptides also include fragments, chimeras, as well as peptides designed to mimic the spatial localization of key amino acid residues within the tissue protective receptor ligands, e.g., EPO. The invention further encompasses methods for treating or preventing a disease or disorder using tissue protective peptides of the current invention. The invention also encompasses methods for enhancing excitable tissue function using tissue protective peptides of the current invention.

A mitral cerclage annuloplasty apparatus comprises a tissue protective device and a knot delivery device. The tissue protective device comprises a first protective tube and a second protective tube. The knot delivery device comprises a tube wherein a loose knot is looped around its distal end through a hole and wherein tight knot is formed when the distal end of the tube is cut open. Alternatively, the knot delivery device comprises an inner tube and outer tube. The inner tube is insertable and rotatable inside the outer tube. When the tubes are in a closed position by rotating either the outer tube or the inner tube, a hole is created near its distal end. When the tubes are in open position by rotating either the outer tube or the inner tube, the hole joins the opening of the outer tube and lengthens.

A tissue protection sleeve for use with a drill alignment assembly for a bone plate includes a tubular body having a first end and a second end. A hole extending from the first end to the second end is formed in the tubular body. The hole has a first center line. An expanded section is formed at the second end, the expanded section has a second center line. A first nose is formed at the first end, the first nose is adapted to fit in a screw hole in the bone plate such that the sleeve is rigidly fixed to the bone plate. The drill alignment assembly further includes an aiming arm adapted to mount to a bone plate and a drill guide insertable in the tissue protection sleeve.

The present invention is directed methods for identifying compounds that have a tissue protective activity using a heteromultimer receptor complex that mediates the tissue protective activities. The complex consists of at least one EPO-R in complex with at least one betac Receptor. These compounds used in the assays to identify tissue protective compounds include, but are not limited to, small molecules and biologics. The compounds identified using these assays can be used to treat various conditions of the central and peripheral nervous systems as well as those of other erythropoietin-responsive or excitable cells, tissues, and organs.

The present disclosure relates to a vessel/tissue protection device having a polymer coated reinforcing layer. The polymer can comprise a biocompatible polymer that will not promote tissue in-growth or attachment, such as segmented polyurethane, polycarbonate urethane, polyether urethane, polyacrylonitrile, etc. The reinforcing layer can comprise any suitable woven, non-woven, knitted, or braided reinforcing polymer, fabric, or foil that is biocompatible and capable of holding a suture, staple, or other attachment device.

The present invention is directed methods for identifying compounds that have a tissue protective activity using a heteromultimer receptor complex that mediates the tissue protective activities. The complex consists of at least one EPO-R in complex with at least one β_c Receptor. These compounds used in the assays to identify tissue protective compounds include, but are not limited to, small molecules and biologics. The compounds identified using these assays can be used to treat or prevent various diseases, disorders, or conditions of the central and peripheral nervous systems as well as those of other erythropoietin-responsive or excitable cells, tissues, and organs.

The present invention relates to the use of adenosine receptor agonists, preferably A₃ receptor agonists, either alone or in combination with other agents for the treatment, prevention and/or management of diseases or disorders associated with under-expression of HIF-1α and/or decreased HIF-1 α activity (e.g., ischemic related disorders). The methods of the invention are directed to methods of reducing tissue damage (e.g., substantially prevention tissue damage, inducing tissue protection) resulting from ischemia orhypoxia. The invention provides methods for treating, preventing and/or ameliorating one or more symptoms of hypoxic or HIF-1α related disorders by administering an A₃ receptor agonist either alone or in combination with other agents.

The mastitis control teat dip composition having a visible indicator aspect of the invention provides a softening, soothing, smoothing, relaxing property, a rapid initial kill, a useful highly pseudoplastic rheology, a barrier/film-forming capacity, a unique antimicrobial composition that is stable over an extended period of time, and unexpected long term microbial control when compared to the prior art materials disclosed in patents and used in the marketplace. The indicator aspect provides ease of visually detecting the material on the animal skin and can indicate efficacy of the material. The compositions of the invention are made by combining an aqueous liquid composition containing the visual indicator combined with the organic components which can be combined with a simple aqueous solution of a salt of chlorous acid, preferably an alkali metal chlorite. The materials after they are combined and blended into a smooth viscous material containing an emollient package generates active antimicrobial chlorine dioxide and can be immediately contacted with the target animals. The compositions of the invention provide stable visual indication, rapid initial kill, consistent long term kill with chemical and rheological stability.